MODERNA INC. DL-_0001
Commented by Nico Popp on October 16th, 2025 | 07:00 CEST
Who definitely deserves credit in the fight against cancer: NetraMark, Moderna, BioNTech
Two biotech pioneers, Moderna and BioNTech, are back in the spotlight after their COVID-19 vaccine success - this time in a race to develop innovative cancer therapies. Both companies rely on mRNA technology to develop personalized cancer vaccines. Speed is crucial here: whoever brings effective treatments to market first could secure billions in market share. At the same time, AI startup NetraMark is entering the stage with novel data analysis that could significantly accelerate research and shape medical progress. We shed light on what is currently driving both the research community and investors.
Read
Commented by Nico Popp on June 26th, 2025 | 07:05 CEST
Decoding the Code of Life – What comes next? Illumina, PanGenomic Health, Moderna
Genetic information is the blueprint of life. Even today, genome sequencing enables us to gain insights that can extend our lives. This is especially true when we can identify certain predispositions to diseases in advance and respond with a healthy lifestyle. Numerous business models are currently emerging around this technology. Some of these are very capital-intensive. Others leverage existing research and artificial intelligence, making them incredibly smart opportunities for investors.
We provide an overview.
Commented by Nico Popp on June 23rd, 2025 | 07:15 CEST
The next cash cow? Quick profits with NetraMark, Moderna, and BioNTech
Do you remember the vaccine race during the coronavirus pandemic? Back then, the duel between BioNTech and CureVac dominated the stock market. Early investors quickly made a fortune. Now, pandemic winner BioNTech aims to swallow up its Swabian competitor. What does this mean, and where is one of the most fascinating industries headed?
Read
Commented by Nico Popp on June 10th, 2025 | 07:20 CEST
Future market – Worth about USD 50 billion: Illumina, Moderna, PanGenomic Health
Medicine is becoming personal. The era of one-size-fits-all drugs is coming to an end. Experts at BCC Research predict that the market for personalized medicine will grow from USD 54.2 billion in 2023 to USD 100.5 billion by 2028. That represents an annual growth rate of 13.2%. Other analysis firms, such as Grand View Research and Market Research Intellect, confirm this promising outlook for investors. All the more reason to take a closer look at Illumina, Moderna, and PanGenomic Health and explore the opportunities they present for investors.
Read
Commented by Stefan Feulner on April 19th, 2023 | 07:30 CEST
Morphosys, Defence Therapeutics, Moderna - The takeover wave keeps rolling
The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions to unmet medical needs. The most recent example is Pfizer's acquisition of Seagen for USD 43 billion. With Big Pharma sitting on filled coffers, this is likely to be just the beginning.
Read
Commented by Stefan Feulner on December 8th, 2022 | 09:25 CET
Core One Labs, BioNxt Solutions, Moderna - Takeover battle in a billion-dollar market
The sharp correction of recent months hit the capital-intensive biotech sector particularly hard. Shares, mainly from the second tier, have, in some cases, had to absorb losses of more than three-quarters of their market value and are trading far below their cash levels. These distortions naturally attract the big players to acquire novel developments at bargain prices.
Read
Commented by Fabian Lorenz on November 3rd, 2022 | 12:01 CET
BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?
BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.
Read
Commented by Carsten Mainitz on September 22nd, 2022 | 10:25 CEST
Moderna, BrainChip Holdings, Infineon - And the winner is?
For many years now, the Boston Consulting Group (BCG) has been selecting the 50 most innovative companies in the world. A few days ago, the hit list was published for the sixteenth time. The top ranks are occupied by Apple, Microsoft, Amazon, Alphabet and Tesla. German companies are only found with Siemens from rank 20. Innovations play an important role for investors because they enable competitive advantages, which sooner or later translates into rising share prices. But global companies are not always the only ones to be considered; it is often lucrative to look at the second tier.
Read
Commented by André Will-Laudien on February 22nd, 2022 | 13:05 CET
BioNTech, Moderna, Valneva, Cardiol Therapeutics: The gold rush is over!
The mild progression of the Omicron variant and the associated massive relaxations of the Corona measures in many countries weighs heavily on the prospects of the vaccine manufacturers. That is because the winter is drawing to a close, clinical shortages are not occurring, and vaccination rates do not want to increase despite massive public campaigns. Meanwhile, even those in power realize that enforcing a general vaccination requirement could become a hot legal ride under the current circumstances. For the biotech sector and vaccine producers, in particular, this is a reason for profit-taking for the time being. Here are a few further ideas.
Read
Commented by Stefan Feulner on January 20th, 2022 | 09:15 CET
Valneva, XPhyto, BioNTech - This is the breakthrough
The shares of vaccine manufacturers are currently experiencing a rollercoaster ride. While BioNTech, Pfizer and Moderna vaccines, based on mRNA technology, continue to reduce their incredible stock market valuation, Valneva, the manufacturer of an inactivated vaccine, has made a brilliant comeback on the stock market floor. The reasons for the good mood were positive data regarding the neutralization of the Omicron variant, which pushed the share up by more than 30% after trading hours.
Read